论文部分内容阅读
目的 评价尿吡啶酚和脱氧吡啶酚对恶性肿瘤骨转移患者的临床意义。方法 采用ELISA方法检测了 2 6例局限性恶性肿瘤、3 5例进展期肿瘤骨转移阴性和 3 4例骨转移阳性的尿吡啶酚和脱氧吡啶酚水平。结果 进展期肿瘤尿吡啶酚和脱氧吡啶酚水平明显高于限局性肿瘤 (P <0 .0 5 ) ;进展期肿瘤骨转移阳性尿吡啶酚和脱氧吡啶酚水平又明显高于骨转移阴性 (P <0 .0 5 )。结论 尿吡啶酚和脱氧吡啶酚在评价进展期肿瘤骨转移和骨吸收中发挥作用。
Objective To evaluate the clinical significance of uridinepyridyl and deoxypyridinol in patients with malignant bone metastases. Methods Twenty-six cases of localized malignancy, 35 cases of advanced bone metastases negative and 34 cases of bone metastasis positive urine pyridinol and deoxypyridinol were detected by ELISA. Results The levels of urinary pyridinol and deoxypyridinol in patients with advanced stage tumors were significantly higher than those in patients with limiting stage tumors (P <0.05). The levels of urinary pyridinol and deoxypyridinol in patients with advanced bone metastasis were significantly higher than those in patients with bone metastasis (P <0 .0 5). Conclusion Uropyridine and deoxypyridin play a role in the evaluation of bone metastasis and bone resorption in advanced stage.